Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CimetrA (MGC Pharmaceuticals)
- Development stage
- Phase 2
- Lead developer
- MGC Pharmaceuticals
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
CimetrA is a nanoparticle micellar formulation developed by MGC Pharmaceuticals, consisting of a synergistic combination of curcumin and boswellia. Designed as an oral spray, it utilizes GraftBio Self-nanoemulsifying Drug Delivery System (SNEDDS) technology to enhance the bioavailability of its active components. The drug acts as an anti-inflammatory and immunomodulatory agent, specifically intended to prevent and treat the cytokine storm or severe inflammation associated with SARS-CoV-2 infection. Clinical evidence from Phase II trials has demonstrated its potential to improve outcomes in patients with moderate COVID-19, reducing the requirement for supplemental oxygen and intensive care. It is also marketed under the brand name ArtemiC in certain jurisdictions.
- Brand names
- CimetrAArtemiC
- Other names
- Curcumin + Boswellia formulation
02
Targets
HMOX1 (Heme oxygenase 1)IFNG (Interferon gamma)IL12 (Interleukin-12)IL1B (Interleukin-1 beta)IL32 (IL-32)IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on CimetrA (MGC Pharmaceuticals).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CimetrA (MGC Pharmaceuticals).